Galmed Pharmaceuticals Ltd.
GLMD
$0.52
-$0.01-1.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -73.01% | -50.14% | 1.15% | -122.97% | 13.41% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 212.82% | 26.22% | -81.67% | 399.17% | -49.35% |
| Change in Net Operating Assets | -517.02% | 183.48% | -109.72% | 782.61% | 80.36% |
| Cash from Operations | -117.31% | -1.94% | -72.00% | -24.68% | 36.23% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 165.80% | 158.31% | 99.38% | -428.23% | -153.47% |
| Cash from Investing | 165.80% | 158.31% | 99.38% | -428.23% | -153.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 165.18% | -96.53% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 165.18% | -96.53% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,155.17% | 117.17% | -124.51% | -47.20% | 108.30% |